Back to search

Article

Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz+lamivudine+tenofovir disoproxil among HIV-1 patients newly starting treatment in China

2023-01-03

Abstract excerpt

<h4>Background: </h4> Though bictegravir/emtricitabine/tenofovir (BIC/TAF/TAF) have been regulatory approved and included in the National Reimbursement Drug List in China, due to the affordability concern, generic version of efavirenz+lamivudine+tenofovir (EFV+3TC+TDF) is still recommended as the 1 st -line therapy in the clinical guideline and widely used in clinical practice. The aim of the study is to assess th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
66450238-2633-5705-a462-d26008d5d2cc
DOI
10.21203/rs.3.rs-2351107/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz+lamivudine+tenofovir disoproxil among HIV-1 patients newly starting treatment in ChinaDOI 10.21203/rs.3.rs-2351107/v1
Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity
Analysis of the Virological Failure Rates and Influencing Factors of ART Regimens Containing Integrase Inhibitors: A Retrospective Analysis from the Real World in ChongqingSemantic proximity
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.Semantic proximity
Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity
Association Between ART Initiation Timing and Treatment Outcomes in Older People Living With HIV: A Longitudinal Study from Baise, ChinaSemantic proximity
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/ISemantic proximity
The Role of Prior HBV Infection and Resistance Mutations on the Efficacy of 3TC/DTG as a Maintenance TherapySemantic proximity
Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.Semantic proximity
Metabolic Effects of Switching from TAF/FTC/RPV to BIC/TAF/FTC in Real-World Clinical SettingSemantic proximity
Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.Semantic proximity
Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label TrialSemantic proximity
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/ISemantic proximity
Select a neighboring publication to make it the new centre.